GT Biopharma (FRA:OXIA) Institutional Ownership: 0.76% (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OXIA GT Biopharma Inc FRA:OXIA
28 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma Institutional Ownership?

GT Biopharma FRA:OXIA 28 Institutional Ownership is 0.76% as of Jul. 26, 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, GT Biopharma's institutional ownership is 0.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, GT Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, GT Biopharma's Float Percentage Of Total Shares Outstanding is 99.97%.

GT Biopharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for GT Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma Institutional Ownership Chart

GT Biopharma Historical Data

The historical data trend for GT Biopharma can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.56 0.29 0.25 0.09 0.08 0.10 0.85 0.83 0.95 0.76
FRA:OXIA
28GF Score
GT Biopharma Inc FRA:OXIA
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.76% mean?
GT Biopharma (FRA:OXIA) has a Institutional Ownership of 0.76% as of Jul. 26, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on GT Biopharma and its competitors.
Is GT Biopharma's Institutional Ownership too high?
GT Biopharma's current Institutional Ownership is 0.76%. Overall, GT Biopharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's Institutional Ownership compare to INTI and HIND?
GT Biopharma's Institutional Ownership of 0.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on GT Biopharma and its competitors. GT Biopharma's current Institutional Ownership is 0.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current Institutional Ownership of 0.76%. The current Institutional Ownership is 0.76%. GT Biopharma's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current Institutional Ownership is 0.76% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
28GF Score

Get the complete analysis for FRA:OXIA

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price